Search

Your search keyword '"Gargosky, Sharron"' showing total 114 results
Start Over Author "Gargosky, Sharron"
114 results on '"Gargosky, Sharron"'

1. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Author

Algazi, Alain P, Twitty, Christopher G, Tsai, Katy K, Le, Mai, Pierce, Robert, Browning, Erica, Hermiz, Reneta, Canton, David A, Bannavong, Donna, Oglesby, Arielle, Francisco, Murray, Fong, Lawrence, Pittet, Mikael J, Arlauckas, Sean P, Garris, Christopher, Levine, Lauren P, Bifulco, Carlos, Ballesteros-Merino, Carmen, Bhatia, Shailender, Gargosky, Sharron, Andtbacka, Robert HI, Fox, Bernard A, Rosenblum, Michael D, and Daud, Adil I

Subjects
Clinical Research, Cancer, Clinical Trials and Supportive Activities, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Case-Control Studies, Female, Follow-Up Studies, Humans, Interleukin-12, Male, Melanoma, Middle Aged, Prognosis, Programmed Cell Death 1 Receptor, Prospective Studies, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; "tavo") electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL).Patients and methodsTavo was administered intratumorally days 1, 5, and 8 every 6 weeks while pembrolizumab (200 mg, i.v.) was administered every 3 weeks. The primary endpoint was objective response rate (ORR) by RECIST, secondary endpoints included duration of response, overall survival and progression-free survival. Toxicity was evaluated by the CTCAE v4. Extensive correlative analysis was done.ResultsThe combination of tavo and pembrolizumab was well tolerated with adverse events similar to those previously reported with pembrolizumab alone. Patients had a 41% ORR (n = 22, RECIST 1.1) with 36% complete responses. Correlative analysis showed that the combination enhanced immune infiltration and sustained the IL-12/IFNγ feed-forward cycle, driving intratumoral cross-presenting dendritic cell subsets with increased TILs, emerging T cell receptor clones and, ultimately, systemic cellular immune responses.ConclusionsThe combination of tavo and pembrolizumab was associated with a higher than expected response rate in this poorly immunogenic population. No new or unexpected toxicities were observed. Correlative analysis showed T cell infiltration with enhanced immunity paralleling the clinical activity in low cpCTL tumors.

Published
2020

2. Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.

Author

Bhatia, Shailender, Longino, Natalie, Miller, Natalie, Kulikauskas, Rima, Iyer, Jayasri, Ibrani, Dafina, Blom, Astrid, Byrd, David, Parvathaneni, Upendra, Twitty, Christopher, Campbell, Jean, Le, Mai, Gargosky, Sharron, Pierce, Robert, Heller, Richard, Nghiem, Paul, and Daud, Adil

Subjects
Aged, Aged, 80 and over, CD8-Positive T-Lymphocytes, Carcinoma, Merkel Cell, Cohort Studies, Electroporation, Female, Gene Transfer Techniques, Humans, Immunotherapy, Interleukin-12, Male, Middle Aged, Neoplasm Metastasis, Patient Safety, Pilot Projects, Plasmids, Skin Neoplasms, Treatment Outcome
Abstract

PURPOSE: IL12 promotes adaptive type I immunity and has demonstrated antitumor efficacy, but systemic administration leads to severe adverse events (AE), including death. This pilot trial investigated safety, efficacy, and immunologic activity of intratumoral delivery of IL12 plasmid DNA (tavo) via in vivo electroporation (i.t.-tavo-EP) in patients with Merkel cell carcinoma (MCC), an aggressive virus-associated skin cancer. PATIENTS AND METHODS: Fifteen patients with MCC with superficial injectable tumor(s) received i.t.-tavo-EP on days 1, 5, and 8 of each cycle. Patients with locoregional MCC (cohort A, N = 3) received one cycle before definitive surgery in week 4. Patients with metastatic MCC (cohort B, N = 12) received up to four cycles total, administered at least 6 weeks apart. Serial tumor and blood samples were collected. RESULTS: All patients successfully completed at least one cycle with transient, mild (grades 1 and 2) AEs and without significant systemic toxicity. Sustained (day 22) intratumoral expression of IL12 protein was observed along with local inflammation and increased tumor-specific CD8+ T-cell infiltration, which led to systemic immunologic and clinical responses. The overall response rate was 25% (3/12) in cohort B, with 2 patients experiencing durable clinical benefit (16 and 55+ months, respectively). Two cohort A patients (1 with pathologic complete remission) were recurrence-free at 44+ and 75+ months, respectively. CONCLUSIONS: I.t.-tavo-EP was safe and feasible without systemic toxicity. Sustained local expression of IL12 protein and local inflammation led to systemic immune responses and clinically meaningful benefit in some patients. Gene electrotransfer, specifically i.t.-tavo-EP, warrants further investigation for immunotherapy of cancer.

Published
2020

3. Effect of novel autologous immune training platform on end-stage patients with cancer.

Author

Pulford, John F, primary, Lederer, James A., additional, Murzin, E, additional, Younger, D, additional, Goh, Jeffrey C., additional, Kitchenadasse, Ganessan, additional, Atkinson, Victoria, additional, Joubert, Warren Lance, additional, Kwatra, Vineet, additional, Okera, Meena, additional, Bishnoi, Sarwan K., additional, Gargosky, Sharron, additional, Borriello, Frank, additional, and Joshi, Rohit, additional

Published
2024
Full Text
View/download PDF

4. 727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours

Author

Joshi, Rohit, primary, Goh, Jeffrey, additional, Gargosky, Sharron, additional, Kitchenadasse, Ganessan, additional, Atkinson, Victoria, additional, Joubert, Warren, additional, Kwatra, Vineet, additional, Okera, Meena, additional, Bishnoi, Sarwan, additional, Nisyrios, George, additional, Lederer, James A, additional, and Borriello, Frank, additional

Published
2023
Full Text
View/download PDF

6. Supplementary Figure Legends from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Author

Algazi, Alain P., primary, Twitty, Christopher G., primary, Tsai, Katy K., primary, Le, Mai, primary, Pierce, Robert, primary, Browning, Erica, primary, Hermiz, Reneta, primary, Canton, David A., primary, Bannavong, Donna, primary, Oglesby, Arielle, primary, Francisco, Murray, primary, Fong, Lawrence, primary, Pittet, Mikael J., primary, Arlauckas, Sean P., primary, Garris, Christopher, primary, Levine, Lauren P., primary, Bifulco, Carlos, primary, Ballesteros-Merino, Carmen, primary, Bhatia, Shailender, primary, Gargosky, Sharron, primary, Andtbacka, Robert H.I., primary, Fox, Bernard A., primary, Rosenblum, Michael D., primary, and Daud, Adil I., primary

Published
2023
Full Text
View/download PDF

7. Table S1 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Author

Algazi, Alain P., primary, Twitty, Christopher G., primary, Tsai, Katy K., primary, Le, Mai, primary, Pierce, Robert, primary, Browning, Erica, primary, Hermiz, Reneta, primary, Canton, David A., primary, Bannavong, Donna, primary, Oglesby, Arielle, primary, Francisco, Murray, primary, Fong, Lawrence, primary, Pittet, Mikael J., primary, Arlauckas, Sean P., primary, Garris, Christopher, primary, Levine, Lauren P., primary, Bifulco, Carlos, primary, Ballesteros-Merino, Carmen, primary, Bhatia, Shailender, primary, Gargosky, Sharron, primary, Andtbacka, Robert H.I., primary, Fox, Bernard A., primary, Rosenblum, Michael D., primary, and Daud, Adil I., primary

Published
2023
Full Text
View/download PDF

8. Figure S2 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Author

Algazi, Alain P., primary, Twitty, Christopher G., primary, Tsai, Katy K., primary, Le, Mai, primary, Pierce, Robert, primary, Browning, Erica, primary, Hermiz, Reneta, primary, Canton, David A., primary, Bannavong, Donna, primary, Oglesby, Arielle, primary, Francisco, Murray, primary, Fong, Lawrence, primary, Pittet, Mikael J., primary, Arlauckas, Sean P., primary, Garris, Christopher, primary, Levine, Lauren P., primary, Bifulco, Carlos, primary, Ballesteros-Merino, Carmen, primary, Bhatia, Shailender, primary, Gargosky, Sharron, primary, Andtbacka, Robert H.I., primary, Fox, Bernard A., primary, Rosenblum, Michael D., primary, and Daud, Adil I., primary

Published
2023
Full Text
View/download PDF

20. Effects of viral virulence on intrauterine growth in SIV-infected fetal Rhesus macaques (Macaca mulatta)

Author

Tarantal, Alice F., Marthas, Marta L., Gargosky, Sharron E., Otysula, Moses, McChesney, Michael B., Miller, Christopher J., and Hendrickx, Andrew G.

Subjects
HIV infection in pregnancy, Fetus -- Growth, Health
Abstract

The amount of growth retardation among fetuses with HIV infection may depend on when during pregnancy the fetus becomes infected with HIV and on the potency of the virus. Researchers infected 26 monkey fetuses with two types of the simian immunodeficiency virus, which is similar to HIV, at different stages of the pregnancies. They found that all monkey fetuses infected with the stronger virus showed evidence of growth retardation and blood abnormalities, but fetuses infected early in the second trimester experienced the most severe effects. These fetuses had low amounts of growth-inducing substances. Fetuses infected with the weaker virus did not experience growth delays. These findings may be applicable to human infants with HIV and growth retardation.

Published
1995

21. In Situ Transfection of Interleukin 12 Plasmid Enhances Anti-PD-1 Immune Response in Patients with Immunologically Quiescent Melanoma

Author

Algazi, Alain P., primary, Twitty, Christopher G., additional, Tsai, Katy K., additional, Le, Mai, additional, Pierce, Robert, additional, Campbell, Jean, additional, Browning, Erica, additional, Hermiz, Renata, additional, Canton, Dave, additional, Bannavong, Donna, additional, Oglesby, Ari, additional, Franco, Murray, additional, Fong, Lawrence, additional, Pittet, Mikael J., additional, Arlaukas, Sean P., additional, Garris, Christopher, additional, Gargosky, Sharron, additional, Levine, Lauren P., additional, Olshen, Adam, additional, Bhatia, Shailender, additional, Ebbinhaus, Scot, additional, Andtbacka, Robert, additional, Fox, Bernard A., additional, Rosenblum, Michael D., additional, and Adlil, Daud, additional

Published
2019
Full Text
View/download PDF

23. Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV mealanoma progressing on either pembrolizumab or nivolumab treatment (PISCES).

Author

Andtbacka, Robert Hans Ingemar, primary, Van Hagen, Tom, additional, Parente, Phillip, additional, Atkinson, Victoria, additional, Puzanov, Igor, additional, Daniels, Gregory A., additional, Thomas, Sajeve Samuel, additional, Long, Anne Poh, additional, Haydon, Andrew Mark, additional, Dudek, Arkadiusz Z., additional, Gargosky, Sharron Erna, additional, Twitty, Chris, additional, and Kirkwood, John M., additional

Published
2018
Full Text
View/download PDF

24. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)

Author

Canton, David A, primary, Shirley, Shawna, additional, Wright, Jocelyn, additional, Connolly, Richard, additional, Burkart, Christoph, additional, Mukhopadhyay, Anandaroop, additional, Twitty, Chris, additional, Qattan, Kristen E, additional, Campbell, Jean S, additional, Le, Mai H, additional, Pierce, Robert H, additional, Gargosky, Sharron, additional, Daud, Adil, additional, and Algazi, Alain, additional

Published
2017
Full Text
View/download PDF

25. Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).

Author

Algazi, Alain Patrick, primary, Tsai, Katy K., additional, Rosenblum, Michael, additional, Fox, Bernard A., additional, Andtbacka, Robert Hans Ingemar, additional, Li, Amy, additional, Takamura, Kathryn Toshimi, additional, Dwyer, Mary, additional, Browning, Erica, additional, Talia, Reneta, additional, Twitty, Chris, additional, Le, Mai H., additional, Gargosky, Sharron, additional, Campbell, Jean S., additional, Ballesteros-Merino, Carmen, additional, Bifulco, Carlo Bruno, additional, Pierce, Robert, additional, and Daud, Adil, additional

Published
2017
Full Text
View/download PDF

26. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Author

Althammer, Sonja, primary, Steele, Keith, additional, Rebelatto, Marlon, additional, Tan, Tze Heng, additional, Wiestler, Tobias, additional, Schmidt, Guenter, additional, Higgs, Brandon, additional, Li, Xia, additional, Shi, Li, additional, Jin, Xiaoping, additional, Antal, Joyce, additional, Gupta, Ashok, additional, Ranade, Koustubh, additional, Binning, Gerd, additional, Bellmunt, Joaquim, additional, de Wit, Ronald, additional, Vaughn, David J., additional, Fradet, Yves, additional, Lee, Jae Lyun, additional, Fong, Lawrence, additional, Vogelzang, Nicholas J., additional, Climent, Miguel A., additional, Petrylak, Daniel P., additional, Choueiri, Toni K., additional, Necchi, Andrea, additional, Gerritsen, Winald, additional, Gurney, Howard, additional, Quinn, David I., additional, Culine, Stéphane, additional, Sternberg, Cora N., additional, Mai, Yabing, additional, Puhlmann, Markus, additional, Perini, Rodolfo F., additional, Bajorin, Dean F., additional, Sharma, Padmanee, additional, Callahan, Margaret K., additional, Calvo, Emiliano, additional, Kim, Joseph W., additional, de Braud, Filipo, additional, Ott, Patrick A., additional, Bono, Petri, additional, Pillai, Rathi N., additional, Morse, Michael, additional, Le, Dung T., additional, Taylor, Matthew, additional, Spilliopoulou, Pavlina, additional, Bendell, Johanna, additional, Jaeger, Dirk, additional, Chan, Emily, additional, Antonia, Scott J., additional, Ascierto, Paolo A., additional, Hennicken, Delphine, additional, Tschaika, Marina, additional, Azrilevich, Alex, additional, Rosenberg, Jonathan, additional, Levy, Ofer, additional, Chan, Christopher, additional, Cojocaru, Gady, additional, Liang, Spencer, additional, Ophir, Eran, additional, Ganguly, Sudipto, additional, Toporik, Amir, additional, Kotturi, Maya, additional, Kfir, Tal Fridman, additional, Murter, Benjamin M., additional, Logronio, Kathryn, additional, Dassa, Liat, additional, Leung, Ling, additional, Greenwald, Shirley, additional, Azulay, Meir, additional, Kumar, Sandeep, additional, Alteber, Zoya, additional, Pan, Xiaoyu, additional, Machlenkin, Arthur, additional, Benita, Yair, additional, Drake, Andrew W., additional, Chajut, Ayelet, additional, Salomon, Ran, additional, Vankin, Ilan, additional, Safyon, Einav, additional, Hunter, John, additional, Levine, Zurit, additional, White, Mark, additional, Leidner, Rom, additional, Kang, Hyunseok, additional, Haddad, Robert, additional, Segal, Neil H., additional, Wirth, Lori J., additional, Ferris, Robert L., additional, Hodi, F. Stephen, additional, Sanborn, Rachel E., additional, Gajewski, Thomas F., additional, Sharfman, William, additional, McDonald, Dan, additional, Srivastava, Shivani, additional, Gu, Xuemin, additional, Phillips, Penny, additional, Passey, Chaitali, additional, Seiwert, Tanguy, additional, Habtetsion, Tsadik, additional, Zhou, Gang, additional, Sakellariou-Thompson, Donastas, additional, Haymaker, Cara, additional, Creasy, Caitlin, additional, Hurd, Mark, additional, Uraoka, Naohiro, additional, Canales, Jaime Rodriguez, additional, Koptez, Scott, additional, Hwu, Patrick, additional, Maitra, Anirban, additional, Bernatchez, Chantale, additional, Coyle, Scott M., additional, Roybel, Kole T., additional, Rupp, Levi J., additional, Santoro, Stephen P., additional, Secrest, Stephanie, additional, Spelman, Michael, additional, Ho, Hanson, additional, Gomes, Tina, additional, Tse, Tiffany, additional, Yung-Wu, Chia, additional, Taunton, Jack, additional, Lim, Wendell, additional, Emtage, Peter, additional, Moudgil, Tarsem, additional, Ballesteros-Merino, Carmen, additional, Hilton, Traci, additional, Paustian, Christopher, additional, Page, David, additional, Urba, Walter, additional, Fox, Bernard, additional, Bell, Bryan, additional, Patel, Ashish, additional, Olafsen, Tove, additional, Satpayev, Daulet, additional, Torgov, Michael, additional, Marchioni, Filippo, additional, Romero, Jason, additional, Jiang, Ziyue Karen, additional, Zamilpa, Charles, additional, Keppler, Jennifer S., additional, Mascioni, Alessandro, additional, Jia, Fang, additional, Lee, Chen-Yu, additional, Gudas, Jean, additional, Sullivan, Ryan J., additional, Hoshida, Yujin, additional, Logan, Theodore, additional, Khushalani, Nikhil, additional, Giobbie-Hurder, Anita, additional, Margolin, Kim, additional, Roder, Joanna, additional, Bhatt, Rupal, additional, Koon, Henry, additional, Olencki, Thomas, additional, Hutson, Thomas, additional, Curti, Brendan, additional, Blackmon, Shauna, additional, Mier, James W., additional, Puzanov, Igor, additional, Roder, Heinrich, additional, Stewart, John, additional, Amin, Asim, additional, Ernstoff, Marc S., additional, Clark, Joseph I., additional, Atkins, Michael B., additional, Kaufman, Howard L., additional, Sosman, Jeffrey, additional, Signoretti, Sabina, additional, McDermott, David F., additional, Anderson, Abraham A., additional, Milhem, Mohammed M., additional, Andtbacka, Robert H. I., additional, Minor, David, additional, Gorski, Kevin S., additional, Baker, Daniel M., additional, Hamid, Omid, additional, Akporiaye, Emmanuel, additional, Koguchi, Yoshinobu, additional, Sutcliffe, Kim, additional, Conder, Kristie, additional, Marron, Thomas, additional, Bhardwaj, Nina, additional, Hammerich, Linda, additional, George, Fiby, additional, Kim-Schulze, Seunghee, additional, Keler, Tibor, additional, Davis, Tom, additional, Crowley, Elizabeth, additional, Salazar, Andres, additional, Brody, Joshua, additional, Monjazeb, Arta, additional, Daly, Megan E., additional, Riess, Jonathan, additional, Li, Tianhong, additional, Murphy, William J., additional, Kelly, Karen, additional, Hu, Zhiwei, additional, Shen, Rulong, additional, Campbell, Amanda, additional, McMichael, Elizabeth, additional, Yu, Lianbo, additional, Ramaswam, Bhuvaneswari, additional, London, Cheryl A., additional, Xu, Tian, additional, Carson, William, additional, Kokolus, Kathleen M., additional, Repasky, Elizabeth A., additional, Schell, Todd D., additional, Drabick, Joseph D., additional, Messenheimer, David J., additional, Jensen, Shawn, additional, Rubinstein, Mark, additional, Andrijauskaite, Kristina, additional, Swiderska-syn, Marzena, additional, Lind, Kristin, additional, Choppin, Agnes, additional, Roell, Marina K., additional, Wrangle, John, additional, Rhode, Peter, additional, Wong, Hing, additional, Ahmad, Shamim, additional, Webb, Mason, additional, Abu-Eid, Rasha, additional, Shrimali, Rajeev, additional, Verma, Vivek, additional, Doroodchi, Atbin, additional, Berrong, Zuzana, additional, Yashar, David, additional, Samara, Raed, additional, Mkrtichyan, Mikayel, additional, Khleif, Samir, additional, Powell, Steven, additional, Gitau, Mark, additional, Sumey, Christopher, additional, Terrell, Andrew, additional, Lohr, Michele, additional, Nowak, Ryan K., additional, McGraw, Steven, additional, Jensen, Ash, additional, Blanchard, Miran, additional, Gold, Kathryn A., additional, Cohen, Ezra E. W., additional, Ellison, Christie, additional, Black, Lora, additional, Lee, John, additional, Spanos, William Chad, additional, Wennerberg, Erik, additional, Schwitzer, Emily, additional, Lhuillier, Claire, additional, Koelwyn, Graeme, additional, Hiner, Rebecca, additional, Jones, Lee, additional, Demaria, Sandra, additional, Amanda, Vandeveer, additional, Greiner, John W., additional, Schlom, Jeffrey, additional, Bookstaver, Michelle, additional, Jewell, Christopher M., additional, Gunderson, Andrew, additional, Boulmay, Brian, additional, Li, Rui, additional, Spieler, Bradley, additional, Happel, Kyle, additional, Feng, Zipei, additional, Dubay, Christopher, additional, Fisher, Brenda, additional, Aung, Sandra, additional, Mederos, Eileen, additional, Bifulco, Carlo B., additional, McNamara, Michael, additional, Bahjat, Keith, additional, Redmond, William, additional, Ochoa, Augusto, additional, Hu, Hong-Ming, additional, Mehta, Adi, additional, Lund-Johansen, Fridtjof, additional, Bedu-Addo, Frank, additional, Conn, Greg, additional, King, Michael, additional, Dutta, Panna, additional, Shepard, Robert, additional, Einstein, Mark, additional, Adams, Sylvia, additional, Wang, Ena, additional, Jin, Ping, additional, Novik, Yelena, additional, Morrison, Debra, additional, Oratz, Ruth, additional, Marincola, Franco M., additional, Stroncek, David, additional, Goldberg, Judith, additional, Formenti, Silvia C., additional, Galon, Jérôme, additional, Mlecnik, Bernhard, additional, Marliot, Florence, additional, Ou, Fang-Shu, additional, Lugli, Alessandro, additional, Zlobec, Inti, additional, Rau, Tilman T., additional, Nagtegaal, Iris D., additional, Vink-Borger, Elisa, additional, Hartmann, Arndt, additional, Geppert, Carol, additional, Roehrl, Michael H., additional, Bavi, Prashant, additional, Ohashi, Pamela S., additional, Wang, Julia Y., additional, Nguyen, Linh T., additional, Han, SeongJun, additional, MacGregor, Heather L., additional, Hafezi-Bakhtiari, Sara, additional, Wouters, Bradley G., additional, Kawakami, Yutaka, additional, Papivanova, Boryana, additional, Xu, Mingli, additional, Fujita, Tomonobu, additional, Hazama, Shoichi, additional, Suzuki, Nobuaki, additional, Nagano, Hiroaki, additional, Okuno, Kiyotaka, additional, Itoh, Kyogo, additional, Zavadova, Eva, additional, Vocka, Michal, additional, Spacek, Jan, additional, Petruzelka, Lubos, additional, Konopasek, Bohuslav, additional, Dundr, Pavel, additional, Skalova, Helena, additional, Torigoe, Toshihiko, additional, Sato, Noriyuki, additional, Furuhata, Tomohisa, additional, Takemasa, Ichiro, additional, Van den Eynde, Marc, additional, Jouret-Mourin, Anne, additional, Machiels, Jean-Pascal, additional, Fredriksen, Tessa, additional, Lafontaine, Lucie, additional, Buttard, Bénédicte, additional, Church, Sarah, additional, Maby, Pauline, additional, Angell, Helen, additional, Angelova, Mihaela, additional, Vasaturo, Angela, additional, Bindea, Gabriela, additional, Berger, Anne, additional, Lagorce, Christine, additional, Patel, Prabhu S., additional, Vora, Hemangini H., additional, Shah, Birva, additional, Patel, Jayendrakumar B., additional, Rajvik, Kruti N., additional, Pandya, Shashank J., additional, Shukla, Shilin N., additional, Wang, Yili, additional, Zhang, Guanjun, additional, Masucci, Giuseppe V., additional, Andersson, Emilia K., additional, Grizzi, Fabio, additional, Laghi, Luigi, additional, Botti, Gerardo, additional, Tatangelo, Fabiana, additional, Delrio, Paolo, additional, Cilberto, Gennaro, additional, Marincola, Franco, additional, Sargent, Daniel J., additional, Fox, Bernard A., additional, Algazi, Alain, additional, Tsai, Katy, additional, Rosenblum, Michael, additional, Nandoskar, Prachi, additional, Li, Amy, additional, Nonomura, John, additional, Takamura, Kathryn, additional, Dwyer, Mary, additional, Browning, Erica, additional, Talia, Reneta, additional, Twitty, Chris, additional, Gargosky, Sharron, additional, Campbell, Jean, additional, Le, Mai, additional, Pierce, Robert H., additional, Daud, Adil, additional, Gartrell, Robyn, additional, Marks, Douglas, additional, Stack, Edward, additional, Lu, Yan, additional, Izaki, Daisuke, additional, Beck, Kristen, additional, Jia, Dan Tong, additional, Armenta, Paul, additional, White-Stern, Ashley, additional, Fu, Yichun, additional, Blake, Zoe, additional, Taback, Bret, additional, Horst, Basil, additional, Saenger, Yvonne M., additional, Leonardo, Steven, additional, Gorden, Keith, additional, Fulton, Ross B., additional, Fraser, Kathryn, additional, Kangas, Takashi O., additional, Walsh, Richard, additional, Ertelt, Kathleen, additional, Graff, Jeremy, additional, Uhlik, Mark, additional, Sims, Jennifer S., additional, Lei, Liang, additional, Tsujiuchi, Takashi, additional, Bruce, Jeffrey N., additional, Canoll, Peter, additional, Tolcher, Anthony W, additional, Alley, Evan W, additional, Chichili, Gurunadh, additional, Canoll, Jan E, additional, Moore, Paul, additional, Bonvini, Ezio, additional, Johnson, Syd, additional, Shankar, Sadhna, additional, Vasselli, James, additional, Wigginton, Jon, additional, and Powderly, John, additional

Published
2016
Full Text
View/download PDF

28. A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Author

Mitchell, Paul LR, primary, Quinn, Michael A, additional, Grant, Peter T, additional, Allen, David G, additional, Jobling, Thomas W, additional, White, Shane C, additional, Zhao, Anne, additional, Karanikas, Vaios, additional, Vaughan, Hilary, additional, Pietersz, Geoffrey, additional, McKenzie, Ian FC, additional, Gargosky, Sharron E, additional, and Loveland, Bruce E, additional

Published
2014
Full Text
View/download PDF

48. Insulin-like growth factors (IGFs): Implications for aging

Author

Cohen, Pinchas, primary, Ocrant, Ian, additional, Fielder, Paul J., additional, Neely, E.Kirk, additional, Gargosky, Sharron E., additional, Deal, Cheri I., additional, Ceda, G.Paolo, additional, Youngman, Oh, additional, Pham, Hung, additional, Lamson, George, additional, Giudice, Linda C., additional, and Rosenfeld, Ron G., additional

Published
1992
Full Text
View/download PDF

49. InsulinLike Growth Factor Binding Protein3 Concentrations and InsulinLike Growth Factor Binding Protein3 Protease Activity in Sera of Patients with Malignant Solid Tumors or Leukemia

Author

MÜLLER, HERMANN L., OH, YOUNGMAN, GARGOSKY, SHARRON E., WILSON, KRISTIN F., LEHRNBECHER, THOMAS, and ROSENFELD, RON G.

Abstract

IGF binding proteins (IGFBP) regulate the bioavailability and bioactivity of IGF. The major IGFBP in serum is IGFBP-3. We investigated whether sera from children with malignancies show alterations in levels of IGFBP-3 as measured by Western ligand blot analysis (WLB) and RIA with αIGFBP-3gl, a specific rabbit polyclonal antibody. Furthermore, IGFBP-3 proteolysis was quantified by densitometric analysis of [125I]IGFBP-3 protease assays, and IGFBP-3 fragments were visualized by Western immunoblot with αIGFBP-3gl. We examined sera from 21 children with solid tumors, five patients with sarcoma who had reached complete remission, and 13 children with acute leukemia. Serum samples were collected at diagnosis, before initiation of therapy. Sera of 10 healthy children served as normal controls. Children with solid tumor or leukemia had significantly higher (p< 0.001) IGFBP-3 protease activity in serum than did normal controls or patients with sarcoma in complete remission. Corresponding to this finding, densitometry of WLB showed lower IGFBP-3 levels in sera of children with malignancies in comparison with normal controls. The negative correlation (p< 0.001, r=-0.80) between IGFBP-3 proteolysis, as measured by [125I]IGFBP-3 protease assay, and IGFBP-3 band density on WLB indicates that proteolysis is the probable reason for reduction of IGFBP-3 on WLB. IGFBP-3 concentrations measured by RIA were in the normal range for most patients, further indicating that differences in serum IGFBP-3 levels measured by WLB reflect protease activity. We conclude that sera from children with malignancies frequently contain protease activity that causes IGFBP-3 cleavage in a way that might affect the tissue availability of IGF. Because many tumor cells are responsive to the mitogenic actions of IGF in vitro, IGFBP-3 proteases in serum could also play a role in tumor progression and metastasis in vivo.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results